ArticleNature immunology2021
mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates.
Open access · bronzeAbstract read
In one paragraph
Article in Nature immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
4.1field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 70 citations in OpenAlex.
- Evaluating southern pigtail macaques as an immunological model for human antibody responses.Scientific reports · 2026Article
- Accelerate the Highly Efficient Development of mRNA Vaccines Through Advanced Computational Methods.MedComm · 2026Review
- Adenoviral vector oropharyngeal spray immunization elicits mucosal immunity and protects against heterologous SARS-CoV-2 infection.NPJ vaccines · 2025Article
- BCG immunization mitigates SARS-CoV-2 replication in macaques via monocyte efferocytosis and neutrophil recruitment in lungs.JCI insight · 2025Article
- A systems biology approach to define SARS-CoV-2 correlates of protection.NPJ vaccines · 2025Article
- Comprehensive review of preclinical evaluation strategies for COVID-19 vaccine candidates: assessing immunogenicity, toxicology, and safety profiles.Iranian journal of microbiology · 2025Review
- A novel and safe SmartCapFrontiers in immunology · 2025Article
- Article
- Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates.Nature immunology · 2024Article
- Variant-proof high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways.Nature communications · 2024Article
- Multi-compartmental diversification of neutralizing antibody lineages dissected in SARS-CoV-2 spike-immunized macaques.Nature communications · 2024Article
- When synthetic biology meets medicine.Life medicine · 2024Review
- Durable immunity to SARS-CoV-2 in both lower and upper airways achieved with a gorilla adenovirus (GRAd) S-2P vaccine in non-human primates.bioRxiv : the preprint server for biology · 2023Article
- Atovaquone and Pibrentasvir Inhibit the SARS-CoV-2 Endoribonuclease and Restrict Infection In Vitro but Not In Vivo.Viruses · 2023Article
- Assessment of Immunogenicity and Efficacy of CV0501 mRNA-Based Omicron COVID-19 Vaccination in Small Animal Models.Vaccines · 2023Article
- Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates.Frontiers in immunology · 2023Article
- Intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in monkeys.Cell · 2022Article
- ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants.Nature communications · 2022Article
- Article
- Are we moving toward ending SARS-CoV-2?Journal of medical virology · 2022Article
Corrections and comments
- Commented on by
Authors and funding
55 authors at 5 institutions in 1 country.
Kizzmekia S CorbettVaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Anne P WernerVaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-2322-6830
Sarah O' ConnellVaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Matthew GagneVaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Lilin LaiCenter for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Department of Pediatrics, Department of Microbiology and Immunology, Emory Vaccine Center, Emory University, Atlanta, GA, USA.
Juan I MolivaVaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Barbara FlynnVaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Angela ChoiModerna, Cambridge, MA, USA.
Matthew KochModerna, Cambridge, MA, USA.
Kathryn E FouldsVaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-4418-6495
Shayne F AndrewVaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Dillon R FlebbeVaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Evan LambVaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Saule T NurmukhambetovaVaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Samantha J ProvostVaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Kevin W BockInfectious Disease Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0001-9454-0937
Mahnaz MinaiInfectious Disease Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Bianca M NagataInfectious Disease Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Alex Van RyBioqual, Rockville, MD, USA.ORCID http://orcid.org/0000-0002-1240-9044
Zackery FlinchbaughBioqual, Rockville, MD, USA.
Timothy S JohnstonVaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0001-9246-6155
Elham Bayat MokhtariVaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Prakriti MudvariVaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Amy R HenryVaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Farida LabouneVaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Becky ChangBioqual, Rockville, MD, USA.
Maciel PortoBioqual, Rockville, MD, USA.
Jaclyn WearBioqual, Rockville, MD, USA.
Gabriela S AlvaradoVaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Seyhan Boyoglu-BarnumVaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
John-Paul M ToddVaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Bridget BartBioqual, Rockville, MD, USA.
Anthony CookBioqual, Rockville, MD, USA.
Alan DodsonBioqual, Rockville, MD, USA.
Laurent PessaintBioqual, Rockville, MD, USA.
Katelyn SteingrebeBioqual, Rockville, MD, USA.
Sayda ElbashirModerna, Cambridge, MA, USA.
Manjari SriparnaVaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-3272-7370
Andrew PekoszDepartment of Microbiology and Immunology, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD, USA.
Hanne AndersenBioqual, Rockville, MD, USA.ORCID http://orcid.org/0000-0003-1103-9608
Kai WuModerna, Cambridge, MA, USA.
Darin K EdwardsModerna, Cambridge, MA, USA.
Swagata KarBioqual, Rockville, MD, USA.
Mark G LewisBioqual, Rockville, MD, USA.ORCID http://orcid.org/0000-0001-7852-0135
Eli BoritzVaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Ian N MooreInfectious Disease Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Andrea CarfiModerna, Cambridge, MA, USA.
Mehul S SutharCenter for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Department of Pediatrics, Department of Microbiology and Immunology, Emory Vaccine Center, Emory University, Atlanta, GA, USA.
Adrian McDermottVaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-0616-9117
Mario RoedererVaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Martha C NasonBiostatistics Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Baltimore, MD, USA.
Nancy J SullivanVaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Daniel C DouekVaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Barney S GrahamVaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. bgraham@nih.gov.ORCID http://orcid.org/0000-0001-8112-0853
Robert A SederVaccine Research Center; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. rseder@mail.nih.gov.ORCID http://orcid.org/0000-0003-3133-0849
National Institutes of Health · USBioqual · USModerna Therapeutics (United States) · USEmory University · USJohns Hopkins University · US
Funding
Non-Human Primate CoreZICAI005103 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI FOULDS, KATHRYN · 2009 to 2025
$22.7MHost Genomic Factors in Infectious Disease Susceptibility ZIAAI005066 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2009 to 2025
$17.9MThe Genome Analysis CoreZICAI005133 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2019 to 2025
$16.9MT Cell Immune Responses To HIV And Other PathogensZIAAI005033 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2009 to 2025
$11.4MThe HIV ReservoirZIAAI005034 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2009 to 2025
$7.5MInnate and Adaptive Immune Responses in SARS-CoV-2 infection (COVID-19)ZIAAI005151 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2020 to 2025
$6.8MmAbs and vaccines against SARS CoV-2ZIAAI005145 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI SULLIVAN, NANCY J · 2020 to 2023
$6.2MInflammationZIAAI005031 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DOUEK, DANIEL CESAR · 2009 to 2024
$5.9MCoronavirus vaccine developmentZIAAI005125 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI GRAHAM, BARNEY · 2014 to 2021
$5.8MDevelopment of a COVID Vaccine Model in NHPZIAAI005150 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI SEDER, ROBERT A · 2020 to 2024
$2.1MNon-Human Primate Core for COVID EffortZICAI005164 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI FOULDS, KATHRYN · 2020 to 2025
$1.3MPersistence and Evolution of SARS-CoV-2ZIAAI005157 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI BORITZ, ELI · 2020 to 2025
$1.3MIntramural NIH HHS Z01 AI005030NIAID NIH HHS HHSN272201400004C
Abstract
B.1.351 is the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant most resistant to antibody neutralization. We demonstrate how the dose and number of immunizations influence protection. Nonhuman primates received two doses of 30 or 100 µg of Moderna's mRNA-1273 vaccine, a single immunization of 30 µg, or no vaccine. Two doses of 100 µg of mRNA-1273 induced 50% inhibitory reciprocal serum dilution neutralizing antibody titers against live SARS-CoV-2 p.Asp614Gly and B.1.351 of 3,300 and 240, respectively. Higher neutralizing responses against B.1.617.2 were also observed after two doses compared to a single dose. After challenge with B.1.351, there was ~4- to 5-log
Indexed as
2019-nCoV Vaccine mRNA-1273AnimalsAntibodies, NeutralizingAntibodies, ViralCell LineChlorocebus aethiopsCOVID-19COVID-19 VaccinesFemaleHumansMacaca mulattaMaleMesocricetusPrimatesRNA, ViralSARS-CoV-22019-nCoV Vaccine mRNA-1273Antibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesRNA, ViralSpike Glycoprotein, Coronavirus
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.